EANS-News: Epigenomics AG Plans Changes in the Composition and Size of its Supervisory Board

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information/Supervisory Board

Berlin, Germany and Seattle, WA, U.S.A., March 16, 2012 (euro adhoc)
- Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American
cancer molecular diagnostics company, announced today that it was
decided to propose to the shareholders of the company at its upcoming
Annual General Meeting (AGM) on May 2, 2012 to vote in favor of a
reduction of the size of the Supervisory Board from currently six to
three members. Furthermore, the company's Chairman, Prof. Dr. Dr.
h.c. Rolf Krebs, announced that for personal reasons he will not
stand for re-election at the upcoming Annual General Meeting.

Prof. Dr. Rolf Krebs (72) has been a member of the Supervisory Board
of Epigenomics AG since 2000 and its Chairman since 2003. During this
period, the company has evolved from a privately held start-up
research company to a publicly listed, worldwide commercial leader in
the field of blood based products for the early detection of cancer.

The Supervisory Board has further resolved to propose Mr. Heino von
Prondzynski for election to the Supervisory Board by the Annual
General Meeting. Mr. von Prondzynski has indicated his willingness to
accept the role as Chairman of the Supervisory Board in case of his
election.

Heino von Prondzynski (62) is an internationally recognized expert
and accomplished business leader in the field of molecular
diagnostics with an extensive network of contacts in the US, Asia and
Europe. Among other career accomplishments, he has been CEO of the
diagnostics division of F. Hoffmann-La Roche Ltd., Basel, Switzerland
and a member of the corporate executive committee of Roche. He is
intimately acquainted with the company, having been a member of the
Supervisory Board of Epigenomics from May 2007 until March 2010.

Prof. Dr. Rolf Krebs said: "I have made a decision not to stand for
re-election at the next Annual General Meeting after careful
deliberation. Heino von Prondzynski represents an excellent and very
committed candidate who is eager to take the responsibility as
Chairman at a decisive point in the company's history. I certainly
will keep following the developments at Epigenomics closely, knowing
that the company has taken several critical steps to move into the
right direction. I am very proud of the accomplishments the company
has made thus far and believe it is the right time to set a clear
signal for a change. I will do my utmost to ensure a smooth
transition going forward. I wish success to Epigenomics and to my
successor."

The proposed changes to the Supervisory Board structure and
composition have been thoroughly planned and were made in line with
last year's decision to reinforce the focus of the company's
operations on the key US market. Heino von Prondzynski has indicated
his intention to work closely with the management team to diligently
explore all viable strategic options for the company in its further
development, including but not limited to the possibility of securing
additional financial resources to support the company's operations
beyond the current cash reach. A main operational goal of the company
remains to gain approval for and subsequently introduce Septin9 based
colorectal cancer screening tests in the US market.

"Subject to my election at the upcoming Annual General Meeting on May
2, 2012, I look forward to becoming a member of the Supervisory Board
of Epigenomics once again", noted Heino von Prondzynski. "From my
previous affiliation as a Supervisory Board member I know the company
very well and have closely followed its development with great
interest. Together with my colleagues in the Supervisory Board and
the management of Epigenomics we will intensify our efforts to
successfully commercialize the company's products in the best
interest of our shareholders."

Geert W. Nygaard, CEO of Epigenomics AG said: "I fully understand and
respect the decision of Prof. Dr. Rolf Krebs to not seek re-election
for personal reasons. Prof. Krebs has been instrumental in leading
the transformation of the company over the last years into a
molecular diagnostics company and has done so with great commitment.
On behalf of the management and employees of Epigenomics we wish to
thank Prof. Dr. Krebs as well as Prof. Dr. Bicker, Mr. Anderson,
Ph.D. and Mr. Frankenne for the trustful collaboration over the last
many years. With Heino von Prondzynski we have found a very
experienced successor for the Chairmanship of the Supervisory Board.
I know Heino von Prondzynski well and look forward to the renewed and
very intensive collaboration in his new role as Chairman of the
Supervisory Board. Given his vast experience and leadership skills I
am certain we will successfully master the challenges ahead of
Epigenomics."

In addition to Mr. von Prondzynski, current members of the
Supervisory Board, Ms. Kessler, Ph.D. and Prof. Dr. Reiter, will be
seeking election at the upcoming Annual General Meeting.

The invitation to the AGM of Epigenomics AG on May 2, 2012 will be
published on Friday, March 23, 2012 on the website of Epigenomics AG
and in the electronic federal gazette. - Ends -

Further Information

Contact Epigenomics AG
Antje Zeise
Manager IR | PR
Epigenomics AG
Tel +49 (0) 30 24345 368
ir@epigenomics.com
www.epigenomics.com

About Epigenomics

Epigenomics (www.epigenomics.com) is a molecular diagnostics company
developing and commercializing a pipeline of proprietary products for
cancer. The Company's products enable doctors to diagnose cancer
earlier and more accurately, leading to improved outcomes for
patients. Epigenomics' lead product, Epi proColon®, is a blood-based
test for the early detection of colorectal cancer, which is currently
marketed in Europe and is in development for the U.S.A. The Company's
technology and products have been validated through multiple
partnerships with leading global diagnostic companies including
Abbott, QIAGEN, Sysmex, and Quest Diagnostics. Epigenomics is an
international company with operations in Europe and the U.S.A.

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain
forward-looking statements concerning Epigenomics AG and its
business. Such statements involve certain known and unknown risks,
uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of Epigenomics AG to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements.
Epigenomics AG is providing this communication as of this date and
does not undertake to update any forward-looking statements contained
herein as a result of new information, future events or otherwise.

The information contained in this communication does not constitute
nor imply an offer to sell or transfer any product, and no product
based on this technology is currently available for sale by
Epigenomics in the United States or Canada. The analytical and
clinical performance characteristics of any Epigenomics product based
on this technology which may be sold at some future time in the U.S.
have not been established.

Further inquiry note:
Antje Zeise | CIRO
Manager IR/PR
Epigenomics AG
Tel: +49 30 24345 386
antje.zeise@epigenomics.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: Epigenomics AG
Kleine Präsidentenstraße 1
D-10178 Berlin
phone: +49 30 24345-0
FAX: +49 30 24345-555
mail: ir@epigenomics.com
WWW: http://www.epigenomics.com
sector: Biotechnology
ISIN: DE000A1K0516
indexes: Prime All Share, Technology All Share
stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart,
regulated dealing/prime standard: Frankfurt
language: English